The FDA has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANCA vasculitis). Related:   Adcomm Split On FDA Approval For ChemoCentryx's Vasculitis Candidate.
Full Story >>
Vote
+5